vTv Therapeutics (VTVT) Non-Current Deffered Revenue (2017 - 2026)

vTv Therapeutics has disclosed Non-Current Deffered Revenue across 10 years of filings, most recently posting $1.8 million for Q2 2026.

• In Q2 2026, Non-Current Deffered Revenue fell 90.2% year-over-year to $1.8 million; the TTM figure through Jun 2026 stood at $1.8 million (down 90.2% YoY), while the FY2025 annual figure was $18.7 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue came in at $1.8 million for Q2 2026 at vTv Therapeutics, roughly flat from $1.8 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $18.7 million in Q2 2022 to a low of $1.8 million in Q1 2026.
• Average Non-Current Deffered Revenue over 5 years is $16.7 million, with a median of $18.7 million recorded in 2022.
• Year-over-year, Non-Current Deffered Revenue jumped 207333.33% in 2022 and slumped 90.2% in 2026.
• Over 5 years, Non-Current Deffered Revenue stood at $18.7 million in 2022, then changed by 0.0% to $18.7 million in 2023, then changed by 0.0% to $18.7 million in 2024, then changed by 0.0% to $18.7 million in 2025, then tumbled by 90.2% to $1.8 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $1.8 million in Q2 2026, $1.8 million in Q1 2026, and $18.7 million in Q4 2025.